Core Insights - The company has made significant progress in index inclusion, corporate governance, and core product development, attracting market attention regarding its Hong Kong Stock Connect eligibility Group 1: Stock Performance - On February 11, 2026, MSCI announced that the company was included in its global small-cap index, effective March 2026, marking it as the only biotech company selected, highlighting its international recognition [2] Group 2: Corporate Structure and Governance - On February 9, 2026, a special shareholder meeting approved the resolution to abolish the supervisory board and amend the articles of association, effective immediately, aimed at optimizing decision-making efficiency [3] Group 3: Product Development Progress - The company is advancing the Phase III clinical study of GFH375 (an oral KRAS G12D inhibitor), which began in November 2025, targeting pancreatic cancer patients, and is the first oral KRAS G12D inhibitor to enter Phase III globally, with a recent investigator meeting held [4] Group 4: Recent Events of Interest - The next review period for the Hong Kong Stock Connect is from January 1 to December 31, 2025, with results expected to be announced on February 25, 2026. As of December 2025, the company's average daily market capitalization meets the inclusion threshold, leading to market speculation about its final inclusion status [5]
劲方医药获MSCI指数纳入，核心产品研发及港股通资格引关注